As I understand, MSB made the announcement on 27th of August 2019 as following:
FDA confirmed that data from the recently completed 159-patient placebo-controlled trial showing that Revascor reduced major mucosal bleeding events can support product marketing authorization through a Biologics License Application (BLA), with confirmatory clinical data.
If the confirmatory data is provided, we might get BLA for Revascor which has a successful rate of 90%.
As I understand, MSB made the announcement on 27th of August...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
-0.095(8.76%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.12 | 98.0¢ | $26.84M | 25.91M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 25272 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 6571 | 1 |
View Market Depth
| Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
99.5¢ |
Change
-0.095 ( 7.78 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.12 | 98.0¢ | 3288218 | ||
| Last updated 15.59pm 30/04/2024 ? | |||||
| MSB (ASX) Chart |